Alnylam Pharma (ALNY) to Discontinue Development of Revusiran; Decision Will Not Affect Patisiran
- S&P 500, Nasdaq dip as interest rate concerns, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- United Airlines maintains forecast after Q1 results top Wall Street estimates
- Dollar eases, near 5-1/2 month high, on hawkish Fed outlook
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- Barnes & Noble Education (BNED) Enters Definitive Agreement with Immersion (IMMR)
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
Morgan Stanley Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 7, 2016 6:32 AM EDTMorgan Stanley downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $36.00.
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $36.21 yesterday.
... MoreAlnylam Pharmaceuticals (ALNY) PT Cut to $77 at Chardan
October 6, 2016 7:39 AM EDTChardan Capital Markets analyst Madhu Kumar cut the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $77.00 (from $115.00) after the company announced the discontinuation of the development of revusiran, a RNAi drug
which was in phase III trials targeting transthyretin (TTR), for the treatment of TTR familial amyloid... More
Alnylam (ALNY) PT Cut to $137 at Needham & Company; Long-Term Investors Should Buy Weakness
October 6, 2016 7:26 AM EDTNeedham & Company analyst Alan Carr cut his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $137.00 (from $152.00) after the company reported last night that the revusiran program has been terminated. An ad hoc review of unblinded Phase 3 ENDEAVOR trial data led the DMC... More
Credit Suisse Cuts Alnylam (ALNY) PT to $50, Keeps 'Outperform'
October 6, 2016 7:23 AM EDTCredit Suisse analyst Alethia Young cut her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $50.00 (from $145.00) but maintained an Outperform after the company announced termination of revusiran.
Young commented, "Lowering TP to $50/sh due to concerns about broader implications to the... More
Alnylam (ALNY) PT Cut to $58 at Jefferies
October 6, 2016 6:47 AM EDTJefferies analyst Gena Wang lowered her price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $58.00 (from $86.00) but maintained a Buy rating after the company announced termination of revusiran Ph3 due to mortality imbalance.
Wang commented, "Following recent discontinuation of ALN-AAT, ALNY announced termination of... More
Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
October 6, 2016 6:44 AM EDTJefferies analyst Biren Amin reiterated his Buy rating and $43 price target on The Medicines Company (NASDAQ: MDCO) saying Alnylam Pharmaceuticals (NASDAQ: ALNY) set back has no read-through to the company's PCSK9 Program.
Amin commented, "ALNY... More
JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
October 6, 2016 6:41 AM EDTJPMorgan downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Neutral with a price target of $51.00 (from $83.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
... MoreBarclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
October 6, 2016 6:41 AM EDTBarclays downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $50.00 (from $85.00).
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
... MoreLeerink Partners Downgrades Alnylam Pharmaceuticals (ALNY) to Market Perform
October 6, 2016 6:39 AM EDTLeerink Partners downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Outperform to Market Perform with a price target of $40.00 (from $107.00) after the company discontinued development of revusiran.
Analyst Michael Schmidt commented, "We are downgrading ALNY to Market Perform following today's news that the company has discontinued development of... More
Medicines Co. (MDCO) Sells-Off with Alnylam (ALNY) Despite Providing Update
October 5, 2016 5:54 PM EDTMedicines Co. (NASDAQ: MDCO) is down 9.1% after-hours after Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC) to suspend dosing, the Company has decided to discontinue development of revusiran, an... More
Alnylam Pharma (ALNY) trading halted with news pending
October 5, 2016 4:25 PM EDTAlnylam Pharma (NASDAQ: ALNY) trading halted with news pending.
... More